ahlam1399
03-23-2016, 01:40 AM
Merck patents on Hepatitis C treatment found valid in dispute with Gilead
NEW YORK, March 22 (Reuters) - A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.
http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2.img (http://da.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/ach.img (http://adchoice.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/ach.htm)http://pi.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2t.imghttp://pi2.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e722ab1/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=vN1hBsAYtjk:_uIlEjIAttE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vN1hBsAYtjk:_uIlEjIAttE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=vN1hBsAYtjk:_uIlEjIAttE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vN1hBsAYtjk:_uIlEjIAttE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=vN1hBsAYtjk:_uIlEjIAttE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/vN1hBsAYtjk
NEW YORK, March 22 (Reuters) - A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.
http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/1/rc.img (http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/1/rc.htm)
http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/2/rc.img (http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/2/rc.htm)
http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/3/rc.img (http://rc.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/rc/3/rc.htm)
http://da.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2.img (http://da.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2.htm)
http://adchoice.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/ach.img (http://adchoice.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/ach.htm)http://pi.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2t.imghttp://pi2.feedsportal.com/r/247395544178/u/49/f/654213/c/35217/s/4e722ab1/sc/28/a2t2.imghttp://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4e722ab1/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=vN1hBsAYtjk:_uIlEjIAttE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vN1hBsAYtjk:_uIlEjIAttE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=vN1hBsAYtjk:_uIlEjIAttE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=vN1hBsAYtjk:_uIlEjIAttE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=vN1hBsAYtjk:_uIlEjIAttE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/vN1hBsAYtjk